Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/18/25 19:01 | 3/18/25 | ACLX | Health | BioPrd | Biological Products, (No Diag | Patel Kavita | CA | D | 15 | S.dm | -7,971 | 91.65 | 0 | -87 | -100 | 0 | D | |||||||||||||||
2/26/25 20:13 | 2/26/25 | ACLX | Health | BioPrd | Biological Products, (No Diag | Elghandour Rami | CA | DO | SEE REMA | 7 | S.dm | -14,819 | 68.07 | 0 | -218 | 149 | D | |||||||||||||||
2/24/25 20:00 | 2/24/25 | ACLX | Health | BioPrd | Biological Products, (No Diag | Heery Christopher | CA | O | CHIEF ME | 19 | S.dm | -22,420 | 60.00 | 0 | -374 | 37 | D | |||||||||||||||
1/10/25 21:36 | 1/7/25 | ACLX | Health | BioPrd | Biological Products, (No Diag | Gilson Michelle | CA | O | CFO | 10 | S.dm | -7,882 | 72.11 | 0 | -109 | 28 | D | |||||||||||||||
4/18/24 16:01 | 4/16/24 | ACLX | Health | BioPrd | Biological Products, (No Diag | Ware Olivia C | CA | D | 2 | S.d | -1,156 | 62.81 | 0 | -18 | -100 | 0 | D | |||||||||||||||
3/25/24 17:30 | 12/14/23 | ACLX | Health | BioPrd | Biological Products, (No Diag | Carroll Jill | PA | D | 2 | S | -60,350 | 59.84 | 0 | -1,009 | 1,983 | I |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |